Current Progress in Stem Cell Therapy for Male Infertility

Adriansyah, Rajendra Falah; Margiana, Ria; Supardi, Supardi; Narulita, Pety

doi:10.1007/s12015-023-10577-3

Stem Cell Rev and Rep

2023

DOI: 10.1007/s12015-023-10577-3

|View full text |Cite

Current Progress in Stem Cell Therapy for Male Infertility

Rajendra Falah Adriansyah,

Ria Margiana,

Supardi Supardi

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

2025

Publication Types

Select...

Article3

Relationship

Self Cite0

Independent3

Authors

Journals

Cited by 3 publications

References 162 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

The Evolutionary Route of in vitro Human Spermatogenesis: What is the Next Destination?

Gizer,

Önen,

Korkusuz

2024

Stem Cell Rev and Rep

View full text Add to dashboard Cite

Malfunction in spermatogenesis due to genetic diseases, trauma, congenital disorders or gonadotoxic treatments results in infertility in approximately 7% of males. The behavior of spermatogonial stem cells (SSCs) within three-dimensional, multifactorial, and dynamic microenvironment implicates a niche that serves as a repository for fertility, since can serve as a source of mature and functional male germ cells. Current protocols enable reprogramming of mature somatic cells into induced pluripotent stem cells (iPSCs) and their limited differentiation to SSCs within the range of 0–5%. However, the resulting human iPSC-derived haploid spermatogenic germ cell yield in terms of number and functionality is currently insufficient for transfer to infertility clinic as a therapeutic tool. In this article, we reviewed the evolution of experimental culture platforms and introduced a novel iPSCs-based approach for in vitro spermatogenesis based on a niche perspective bearing cellular, chemical, and physical factors that provide the complex arrangement of testicular seminiferous tubules embedded within a vascularized stroma. We believe that bioengineered organoids supported by smart bio-printed tubules and microfluidic organ-on-a-chip systems offer efficient, precise, personalized platforms for autologous pluripotent stem cell sources to undergo the spermatogenetic cycle, presenting a promising tool for infertile male patients with complete testicular aplasia. Graphical Abstract

show abstract

The Evolutionary Route of in vitro Human Spermatogenesis: What is the Next Destination?

Gizer,

Önen,

Korkusuz

2024

Stem Cell Rev and Rep

View full text Add to dashboard Cite

show abstract

Harnessing the potential of tissue engineering to target male infertility: Insights into testicular regeneration

Forouzandegan,

Sadeghmousavi,

Heidari

et al. 2025

Tissue and Cell

View full text Add to dashboard Cite

Enhancing Spermatogenesis in Non-obstructive Azoospermia Through Mesenchymal Stem Cell Therapy22

Margiana

2024

CSCR

View full text Add to dashboard Cite

Stem cells hold great promise as novel and encouraging therapeutic tools in the treatment of degenerative disorders due to their differentiation potential while maintaining the capability to self-renewal and their unlimited ability to divide and regenerate tissue. A variety of different types of stem cells can be used in cell therapy. Among these, mesenchymal stem cell (MSC) therapy has gradually established itself as a novel method for treating damaged tissues that need restoration and renewal. Male infertility is an important health challenge affecting approximately 8-12% of people around the world. This abnormality can be caused by primary, congenital, acquired, or idiopathic reasons. Men with no sperm in their semen have a condition called azoospermia, caused by non-obstructive (NOA) causes and post-testicular obstructive causes. Accumulating evidence has shown that various types of MSCs can differentiate into germ cells and improve spermatogenesis in the seminiferous tubules of animal models. In addition, recent studies in animal models have exhibited that extracellular vesicles derived from MSCs can stimulate the progression of spermatogenesis and germ cell regeneration in the recipient testes. In spite of the fact that various improvements have been made in the treatment of azoospermia disorder in animal models by MSC or their extracellular vesicles, no clinical trials have been carried out to test their therapeutic effect on the NOA. In this review, we summarize the potential of MSC transplantation for treating infertility caused by NOA.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Current Progress in Stem Cell Therapy for Male Infertility

Cited by 3 publications

References 162 publications

The Evolutionary Route of in vitro Human Spermatogenesis: What is the Next Destination?

The Evolutionary Route of in vitro Human Spermatogenesis: What is the Next Destination?

Harnessing the potential of tissue engineering to target male infertility: Insights into testicular regeneration

Enhancing Spermatogenesis in Non-obstructive Azoospermia Through Mesenchymal Stem Cell Therapy22

Contact Info

Product

Resources

About